NCT02467504View on ClinicalTrials.gov

Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

January 15, 2017

Study Completion Date

August 31, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

hrIL-2 active

hrIL-2 active (1 million U doses of hrIL-2s.c.injection)

DRUG

hrIL-2 placebo

hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)

DRUG

MTX

Methotrexate (oral administration)

DRUG

Folic Acid

Folic Acid (oral administration)

DRUG

Loxoprofen

Loxoprofen (oral administration)

Trial Locations (1)

100044

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Monash University

OTHER

collaborator

Beijing ShuangLu Pharmaceutical Co., Ltd.

OTHER

lead

Peking University People's Hospital

OTHER

NCT02467504 - Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter